Literature DB >> 10780773

Validation of assays for inflammatory mediators in sputum.

R A Stockley1, D L Bayley.   

Abstract

Commercially available immune assays are being used with increasing frequency in the study of lung inflammation. However, their performance in complex biological fluids is rarely assessed. The authors wished to assess their reliability to determine whether the results obtained in sputum samples can be easily interpreted. The reproducibility of several such assays was therefore determined together with their ability to recover known amounts of pure reagent. Sputum sol phase was obtained from several patients with chronic lung disease and used together with the reagents in a series of "spiking" and dilutional experiments. Results confirmed that the enzyme assay for myeloperoxidase and the immune assays for interleukin-8, leukotriene B4 and secretory leukoproteinase inhibitor were all reproducible (intra-assay coefficient of variation 3.8-7.7%). Furthermore, each of these assays gave >85% recovery of a "spike" with pure reagent. However, the immune assay for myeloperoxidase (although reproducible) gave poor recovery and was dependent on the degree of sample dilution and elastase content. These studies confirm that the reliabilities of fluid phase measurements should be assessed before being widely applied to complex biological samples.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780773     DOI: 10.1034/j.1399-3003.2000.15d24.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

2.  Blood Neutrophils Are Reprogrammed in Bronchiectasis.

Authors:  Pallavi Bedi; Donald J Davidson; Brian J McHugh; Adriano G Rossi; Adam T Hill
Journal:  Am J Respir Crit Care Med       Date:  2018-10-01       Impact factor: 21.405

3.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

4.  Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8.

Authors:  I S Woolhouse; D L Bayley; R A Stockley
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

5.  Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis.

Authors:  I S Woolhouse; D L Bayley; R A Stockley
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

6.  Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis.

Authors:  A J White; S Gompertz; D L Bayley; S L Hill; C O'Brien; I Unsal; R A Stockley
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

7.  Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.

Authors:  Derek W Russell; Amit Gaggar; George M Solomon
Journal:  Ann Am Thorac Soc       Date:  2016-04

8.  Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous diseases.

Authors:  E Fireman; Z Kraiem; O Sade; J Greif; Z Fireman
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

9.  Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study.

Authors:  David G Parr; Andrew J White; Darren L Bayley; Peter J Guest; Robert A Stockley
Journal:  Respir Res       Date:  2006-11-18

10.  Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome.

Authors:  Nazim Nathani; Gavin D Perkins; William Tunnicliffe; Nick Murphy; Mav Manji; David R Thickett
Journal:  Crit Care       Date:  2008-01-23       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.